Dear Editor,

The intestinal tract may be an important reservoir for antibiotic-resistant genes \[[@B1]\]. Determining the prevalence of quinolone resistance in intestinal bacteria within the community is important for both healthy subjects and hospital patients as quinolone is one of the most commonly used antibiotics in China. The prevalence of plasmid-mediated quinolone resistance (PMQR) gene-harboring *Enterobacteriaceae* in the gut flora among healthy humans was previously unknown, so we assessed the prevalence of PMQR genes among commensal *Escherichia coli* in healthy persons from one region in China. This study was approved by the Ethics Committee of the Fujian Medical University Union Hospital (No. 2012KY085). Written informed consent was obtained from all participants.

From July to October 2013, fecal samples were collected at a teaching hospital in Fuzhou (China) from healthy subjects at their annual physical examination. None of the subjects had been exposed to antibiotics or a hospital environment in the three months prior to sample collection. A total of 429 fecal samples, one per person, were examined. Samples were screened using MacConkey agar plates supplemented with levofloxacin (0.125 µg/mL). Among the 429 participants, 220 (51.3%) were males and 209 (48.7%) were females. The age range was 6--84 years (median age: 48 years). Four participants were under 18 years old, and the rest were over 18 years.

In this study, 89.0% (382/429) of the samples were colonized with *E. coli* with reduced quinolone susceptibility. Previous research on community carriage of quinolone-resistant *Enterobacteriaceae* described carriage rates that were highly different from our findings \[[@B2][@B3]\], probably because of factors such as regional differences in climate, eating patterns, and sanitary conditions.

PMQR determinants were screened by PCR in 382 levofloxacin-resistant *E. coli* fecal isolates as previously described \[[@B4]\]. The results showed that 31.4% (120/382) of fecal *E. coli* harbored PMQR determinants. Among 120 PMQR-positive isolates, *qnr* genes were the most common determinants (41.7%), followed by *aac* *(6′)*-*Ib*-*cr* (36.7%) and *oqxAB* (35.8%) ([Table 1](#T1){ref-type="table"}). Among 50 *qnr*-positive *E. coli*, *qnrS1* was the most common PMQR gene (94.0%), as reported by previous studies \[[@B3][@B4]\]. *qnrB1* was detected in four isolates ([Table 1](#T1){ref-type="table"}); *qnrA*, *qnrC*, and *qnrD* were not found. Usually, aac *(6′)*-*Ib*-*cr* is more common than *qnr* genes \[[@B5]\]. A previous study showed that strain selection criteria may underestimate the presence of bacteria harboring *aac* *(6′)*-*Ib*-*cr* \[[@B6]\], which probably explains the low prevalence of this PMQR determinant in our study.

PMQR determinants are frequently associated with extended spectrum beta-lactamase (ESBL) in *Enterobacteriaceae* \[[@B5]\]. In this study, β-lactamase genes (*bla*TEM, *bla*SHV, and *bla*CTX-M) were detected as described previously \[[@B7]\]. Ninety-nine (82.5%) strains co-harbored β-lactamase genes. *bla*~TEM-1~, *bla*~CTX-M-1~ group, and *bla*~CTX-M-9~ group were found in 72 (72.3%), 24 (24.2%), and 21 (21.2%) isolates, respectively. Overall, *bla*~CTX-M-15~ was the predominant ESBL genotype (20.2%, 20/99), followed by *bla*~CTX-M-14~ (13.1%, 13/99), *bla*~CTX-M-65~ (5.1%, 5/99), *bla*~CTX-M-79~ (4.0%, 4/99), *bla*~CTX-M-27~ (2.0%, 2/99), and *bla*~CTX-M-98~ (1.0%, 1/99). *bla*~SHV~, *bla*~CTX-M-2~ group, and *bla*~CTX-M-8~ group were not found. Different PMQR genes tend to co-exist with specific cephalosporin resistance genes. For example, *qnrA* and *qnrB* are usually found with *bla*CTX-M and *bla*SHV, and *qnrS* is always located on plasmids carrying *bla*TEM-1 \[[@B8]\]. These might explain why in our study, most PMQR-positive isolates produced *bla*TEM-1 and less than half of the strains co-harbored *bla*CTX-M.

PMQR-harboring fecal *E. coli* were tested for susceptibility toward nine different antimicrobials according to the CLSI \[[@B9]\]. These isolates showed high resistance against nalidixic acid (100%, 120/120), ciprofloxacin (78.3%, 94/120), and levofloxacin (66.7%, 80/120). Resistance rates to gentamicin, cefotaxime, cefepime, and amikacin were less than 50% ([Table 2](#T2){ref-type="table"}). All strains were susceptible to imipenem. Antibiotic susceptibilities of β-lactamase gene-positive and β-lactamase gene-negative PMQR-positive *E. coli* are shown in [Table 2](#T2){ref-type="table"}. A higher percentage of resistance to cefotaxime was observed in β-lactamase gene-positive isolates than in negative isolates ([Table 2](#T2){ref-type="table"}).

Molecular characteristics of PMQR-positive *E. coli* fecal isolates were determined, including phylogenetic grouping and random amplified polymorphic DNA analysis as previously described \[[@B2][@B7]\]. The distribution of PMQR genes in *E. coli* phylogenetic groups is shown in [Table 1](#T1){ref-type="table"}. PMQR-positive *E. coli* fecal strains (120) were categorized into 71 genotypes; three strains were non-typeable, suggesting a non-clonal origin.

In conclusion, our study demonstrated a high prevalence of quinolone-resistant *E. coli* colonization in the gut flora of healthy subjects in one region of China. PMQR determinants were widely disseminated among those strains. Rational antibiotic use is imperative, and intervention programs and policies are urgently needed to control the colonization and dissemination of quinolone-resistant *Enterobacteriaceae* to promote public health in China.
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###### Distribution of PMQR genes in *E. coli* phylogenetic groups and the corresponding fluoroquinolone minimal inhibitory concentration (MIC) ranges
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  PMQR genes                             N     Phylogenetic group (N, %)   Ciprofloxacin (μg/mL)   Levofloxacin (μg/mL)                                                 
  -------------------------------------- ----- --------------------------- ----------------------- ---------------------- ----------- -------- ---- ----- -------- ---- ----
  *qnrS1*                                38    25 (65.8)                   9 (23.7)                4 (10.5)               0           1--64    4    32    1--128   4    32
  *aac(6′)Ib-cr*                         33    16 (48.5)                   6 (18.2)                3 (9.1)                8 (24.2)    1--256   32   128   2--64    8    32
  *oqxA*+*oqxB*                          32    18 (56.3)                   10 (31.3)               0                      4 (12.5)    1--64    8    32    1--32    8    16
  *qnrS1*+*oqxA*+*oqxB*                  6     3 (50)                      3 (50)                  0                      0           1--8     2    8     1--32    4    32
  *aac(6′)Ib-cr*+*oqxA*+*oqxB*           4     2 (50)                      2 (50)                  0                      0           8--32    16   32    16--32   16   32
  *qnrS1*+*aac(6′)Ib-cr*                 2     2 (100)                     0                       0                      0           \-       \-   \-    \-       \-   \-
  *qnrB1*+*aac(6′)Ib-cr*                 2     2 (100)                     0                       0                      0           \-       \-   \-    \-       \-   \-
  *oqxA*                                 1     0                           0                       0                      1           \-       \-   \-    \-       \-   \-
  *qnrS1*+*qnrB1*+*aac(6′)Ib-cr*         1     1                           0                       0                      0           \-       \-   \-    \-       \-   \-
  *qnrB1*+*aac(6′)Ib-cr*+*oqxA*+*oqxB*   1     1                           0                       0                      0           \-       \-   \-    \-       \-   \-
  Total                                  120   70 (58.3)                   30 (25.0)               7 (5.8)                13 (16.7)                                     

Abbreviations: MIC50, minimum inhibitory concentration required to kill 50% of the microbial population; MIC90, minimum inhibitory concentration required to kill 90% of the microbial population.

###### Association between antimicrobial susceptibility and β-lactamase genes in PMQR-positive *E. coli* isolates
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  Antimicrobial agents   MIC (μg/mL)   Resistance rate (%)                                                   
  ---------------------- ------------- --------------------- ----- ------ ------ ------ ------ ------ ------ -------
  Nalidixic acid         16--512       512                   512   0      100    0      100    0      100    \-
  Ciprofloxacin          0.5--512      8                     64    9.2    78.3   8.1    81.8   14.3   57.1   0.407
  Levofloxacin           0.5--256      8                     32    10.8   66.7   10.1   71.7   14.3   42.9   0.463
  Cefotaxime             0.125--512    0.125                 128   56.7   43.3   51.5   48.5   85.7   14.3   0.004
  Gentamicin             0.125--512    2                     128   52.5   45.8   49.5   48.5   71.4   28.6   0.081
  Cefepime               0.125--512    0.125                 8     92.5   4.2    92.9   3.0    95.2   4.8    0.555
  Amikacin               0.125--512    2                     2     97.5   2.5    97.0   3.0    100    0      1.000
  Imipenem               0.125--4      0.25                  0.5   100    0      100    0      100    0      \-

^\*^Statistical significance (*P*) was calculated using the Pearson Chi-square test in terms of the number of resistant strains and susceptible strains in the β-lactamase gene-positive and β-lactamase gene-negative groups. Intermediate isolates were considered non-susceptible isolates.

Abbreviations: S, susceptible; R, resistant; MIC, minimum inhibitory concentration; MIC~50~, minimum inhibitory concentration required to kill 50% of the microbial population; MIC~90~, minimum inhibitory concentration required to kill 90% of the microbial population.
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